The purpose of the study is to evaluate how effective the TCP-25 gel is in promoting wound healing and improving symptoms of EB. The study will also assess the safety and how well patients tolerate the gel. Participants will be randomly assigned to receive either the TCP-25 gel or a similar gel that does not contain the active ingredient. The study will be conducted in a way that neither the participants nor the researchers know which gel is being used, to ensure unbiased results.

Throughout the study, participants will apply the gel to their wounds and attend regular check-ups to monitor their progress. The study will last for several weeks, during which the size of the wounds, any changes in pain levels, and overall skin condition will be observed. The study aims to provide valuable information on the potential benefits of TCP-25 for people living with EB.

The purpose of the study is to evaluate the safety of this new treatment. Participants will receive the genetically corrected skin graft, and their health will be monitored over time. The study will follow participants for a total of five years, with regular check-ups at various intervals to ensure the treatment is safe and to observe any changes in the skin. These check-ups will include skin examinations and other assessments to track the progress of the grafted skin and overall health.

Throughout the study, researchers will look for any side effects or reactions to the treatment. They will also assess how well the grafted skin is healing and whether it improves the condition of the skin. This trial aims to provide valuable information on whether this innovative approach can offer a new option for managing RDEB and improving the quality of life for those affected by this challenging condition.

The purpose of the study is to assess the safety and effectiveness of Rigosertib Sodium in patients with RDEB who have advanced SCC that has not responded to standard treatments. Participants will receive Rigosertib Sodium either orally or through an infusion. The oral treatment involves taking capsules daily for three weeks followed by a one-week break. The infusion treatment involves receiving the medication over a 72-hour period on the first three days of a two-week cycle for the first eight cycles, and then on the first three days of a four-week cycle thereafter.

The study will last for up to 52 weeks, during which the response to the treatment will be monitored using imaging techniques like CT or MR scans. Additionally, the study will look at the impact of the treatment on the quality of life of participants and analyze certain biological markers related to the pathways affected by Rigosertib Sodium. The goal is to determine how well the treatment works and how it affects the patients’ overall health and well-being.

The main goal of the study is to assess the safety of these cells when they are injected into the skin of patients with epidermolysis bullosa. Participants in the study will receive injections of the cell treatment, and some may receive a placebo. The study will monitor participants for any side effects, such as severe reactions at the injection site or allergic responses, as well as any changes in the condition of their skin. The study will also look at how the treatment affects the healing of skin lesions and the overall area of affected skin.

Throughout the study, participants will be asked to report on their experiences, including any itching or ease of changing wound dressings. The study is designed to gather important information that could lead to new treatment options for people living with epidermolysis bullosa. The trial is expected to continue until 2025, providing valuable insights into the potential benefits and risks of using these special cells for treating this challenging condition.

The purpose of the study is to evaluate how effective and safe the Diacerein 1% Ointment is for treating EBS. Participants in the study will be randomly assigned to receive either the Diacerein ointment or a vehicle ointment, which is a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. The study will last for several weeks, during which participants will apply the ointment to their skin and attend regular check-ups to monitor their progress and any side effects.

Throughout the study, participants will be asked to report any changes in their symptoms, such as pain or itching, and any other health issues they experience. The study aims to determine if the Diacerein 1% Ointment can successfully reduce the severity of EBS symptoms and improve the quality of life for those affected by this condition. Participants will also have the opportunity to continue using the ointment in an open-label extension phase, where everyone will receive the actual treatment, to further assess its long-term benefits and safety.

The purpose of the study is to assess how well apremilast works in reducing the symptoms of EBS, such as the number of new blisters, and to evaluate its safety for patients. The study will follow a specific design where patients will receive the medication in different phases to observe its effects. Participants will take Otezla in the form of film-coated tablets, which are taken orally. The maximum daily dose is 60 milligrams, and the treatment period can last up to 16 weeks. During the study, some participants may receive a placebo, which is a substance with no active medication, to compare the effects.

Throughout the trial, researchers will monitor various aspects of the patients’ health, including the severity of their condition, any itching or pain they experience, and their overall quality of life. The study also aims to validate a new scale for measuring the severity of EBS. By the end of the trial, the researchers hope to gather valuable information on the potential benefits and risks of using apremilast for treating EBS, which could lead to improved treatment options for those affected by this challenging condition.

Participants in the study will take deucravacitinib, which is provided in the form of a 6 mg film-coated tablet, taken orally. The study will last for 44 weeks and will follow a specific pattern where the medication is given, then stopped, and then given again. This approach helps researchers understand how the medication works over time. The study will also look at how the medication affects the severity of the skin conditions, the level of itch and pain experienced, and the overall quality of life of the participants.

Throughout the study, the safety of deucravacitinib will be closely monitored. Researchers will also collect information on how well participants follow the treatment plan and will analyze certain proteins in the body, known as cytokines, to understand their role in these skin conditions. The study aims to provide valuable insights into the potential benefits of deucravacitinib for people living with these challenging skin disorders.

The purpose of the study is to evaluate the safety and effectiveness of this treatment compared to a placebo. Participants will receive the treatment or placebo over a period of time, and their progress will be monitored to see if there is any improvement in their condition. The study will also include an open-label part, where all participants will receive the treatment, to further assess its safety and effectiveness.

Throughout the study, participants will have regular check-ups to monitor their health and the condition of their skin. The study aims to see if the treatment can help close wounds, reduce pain and itching, and improve the overall quality of life for those with epidermolysis bullosa. The trial will also look at any potential side effects or immune reactions to the treatment. The study is expected to continue until 2025, with participants being closely monitored throughout the process.

Participants in the study will take cholestyramine, which is a type of medication that comes in a powder form and is mixed with water to drink. The study will compare the levels of persistent organic pollutants in the blood before the surgery and four months after the surgery. This will help researchers understand if cholestyramine can help reduce these pollutants in the body.

The study will last until June 2025, and it aims to provide valuable information on how cholestyramine might help manage the levels of persistent organic pollutants in people with obesity who are undergoing bariatric surgery. This research could potentially lead to better health outcomes for individuals dealing with obesity and related health issues.